Comparison of performance of one-color and two-color gene-expression analyses in predicting clinical endpoints of neuroblastoma patients.
about
Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47Quality assurance of RNA expression profiling in clinical laboratoriesTime-lapse imaging of neuroblastoma cells to determine cell fate upon gene knockdownThe MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models.k-Nearest neighbor models for microarray gene expression analysis and clinical outcome prediction.Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1FOXP1 inhibits cell growth and attenuates tumorigenicity of neuroblastoma.Reverse engineering the neuroblastoma regulatory network uncovers MAX as one of the master regulators of tumor progression.Evaluation of gene expression classification studies: factors associated with classification performanceComparison of RNA-seq and microarray-based models for clinical endpoint prediction.MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma.The Mechanism by Which MYCN Amplification Confers an Enhanced Sensitivity to a PCNA-Derived Cell Permeable Peptide in Neuroblastoma Cells.Clinical implementation of RNA signatures for pharmacogenomic decision-makingHox-C9 activates the intrinsic pathway of apoptosis and is associated with spontaneous regression in neuroblastomaAn 18 gene expression-based score classifier predicts the clinical outcome in stage 4 neuroblastoma.The FDA's Experience with Emerging Genomics Technologies-Past, Present, and FutureMYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma.Transcriptional profiling to identify biomarkers of disease and drug response.Pharmacogenomic biomarkers for personalized medicine.Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma.microRNA-449a functions as a tumor suppressor in neuroblastoma through inducing cell differentiation and cell cycle arrest.Effects of a novel long noncoding RNA, lncUSMycN, on N-Myc expression and neuroblastoma progression.Standardization efforts enabling next-generation sequencing and microarray based biomarkers for precision medicine.Upregulation of LYAR induces neuroblastoma cell proliferation and survival.Signaling pathway models as biomarkers: Patient-specific simulations of JNK activity predict the survival of neuroblastoma patients.Transcription factor activating protein 2 beta (TFAP2B) mediates noradrenergic neuronal differentiation in neuroblastomaIntegrative genomics reveals hypoxia inducible genes that are associated with a poor prognosis in neuroblastoma patients.Analyzing abundance of mRNA molecules with a near-infrared fluorescence technique.Wnt signalling is a bi-directional vulnerability of cancer cells.Gene expression and molecular pathway activation signatures of MYCN-amplified neuroblastomas.Mutation status coupled with RNA-sequencing data can efficiently identify important non-significantly mutated genes serving as diagnostic biomarkers of endometrial cancer.
P2860
Q24561405-A56C19C4-526E-4351-8611-ACFF91687840Q26866455-35DC257D-0F0D-49BF-A776-7E13C47AED2FQ27332436-4B0721C0-0290-4811-97CF-48EEE077C721Q30512428-69817A26-85A8-4E6C-B666-3E9771A6AB5DQ34059963-16EDB4C9-6827-456A-BA1B-8703830E4268Q34100931-56B06AA5-F329-4151-B5C0-1E6E38E00207Q34611561-5D264AB2-0D51-4B15-93B8-A3742B7C52B4Q35070297-BAEBC005-D033-4238-A35B-6B465D63C745Q35158226-1902D3D6-BE1F-4169-B945-FD216E8FA3CCQ35863265-B78EBDA3-8AC8-4832-8DDB-BA3B6433B98CQ36021061-A1EA88DA-B0ED-4900-91AB-87FDE62F2314Q36437713-63CF68ED-62E5-4FB0-A2FF-BAC39CDC8B24Q36441512-124BDFBD-DE40-48C2-95F3-92657148259DQ36890247-D06AE076-BCE8-41B6-963D-B5835687CA9FQ36911240-EF56DB2C-F1E3-41E2-A07C-BAF0A65EE953Q37151755-DBD4F797-C941-4965-838A-9CD5EEC98E95Q37686989-CEF71F0B-5B6C-4B13-8BD9-A23BAE4B9EC0Q37844547-465FE3DB-4488-43AB-AACC-AE44771C3D30Q38112822-028F8814-7313-46DB-8AA5-694FCE44F885Q38294764-775BF1BD-229A-4CD2-A214-E96F181900F9Q38300511-E9FFE2A9-0B02-4BC0-BBEE-89C674D846E0Q38306526-AB91EDB2-36B4-42C5-971F-61C7F969D4B6Q38616603-19E932E3-FF27-48D4-B6FE-D14266C153CAQ38689375-47BDFAE9-A080-4E09-B2F7-270C64828519Q38809615-D97BEC83-25C9-4D44-AB26-0F0793E725CEQ38817378-66ADD8FF-4704-4B69-9E02-8E3CDD5C7514Q39264816-660F9341-5B4A-4B2B-9F5F-3B9505088480Q39299170-7EE1C17A-BDB2-4B70-A83E-850CD822BF27Q42321100-2D64CFE2-6FB6-4C3D-93F3-DC1B36860AFEQ44644664-427FFA9D-5506-40DA-8F99-CFE8B5959771Q47131591-2B8D13BD-5293-46E5-92A0-736EE4E29CFC
P2860
Comparison of performance of one-color and two-color gene-expression analyses in predicting clinical endpoints of neuroblastoma patients.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Comparison of performance of o ...... nts of neuroblastoma patients.
@ast
Comparison of performance of o ...... nts of neuroblastoma patients.
@en
Comparison of performance of o ...... nts of neuroblastoma patients.
@nl
type
label
Comparison of performance of o ...... nts of neuroblastoma patients.
@ast
Comparison of performance of o ...... nts of neuroblastoma patients.
@en
Comparison of performance of o ...... nts of neuroblastoma patients.
@nl
prefLabel
Comparison of performance of o ...... nts of neuroblastoma patients.
@ast
Comparison of performance of o ...... nts of neuroblastoma patients.
@en
Comparison of performance of o ...... nts of neuroblastoma patients.
@nl
P2093
P2860
P356
P1476
Comparison of performance of o ...... nts of neuroblastoma patients.
@en
P2093
A Oberthuer
F Berthold
F Westermann
R D Wolfinger
P2860
P2888
P304
P356
10.1038/TPJ.2010.53
P577
2010-08-01T00:00:00Z
P5875
P6179
1040150746